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Mortality in patients with pulmonary tuberculosis remains high, especially in those who develop acute
respiratory distress syndrome (ARDS). We report on a-48-year-old man with ARDS due to severe pul-
monary tuberculosis who was rescued by extracorporeal membrane oxygenation (ECMO). He was
initially hospitalized in the intensive care unit and noninvasive positive-pressure ventilation started. He
was also administered anti-tuberculosis drugs and received systemic corticosteroid therapy. Six days
later, further deterioration of gas exchange prompted the decision to intubate. However, he experienced
progressive deterioration of arterial oxygenation despite conventional ventilatory support. We therefore
decided to administer ECMO on day 9. After initiation of these treatments and ECMO support, pulmonary
inﬁltrate and oxygenation status gradually improved and ECMO was discontinued on day 52. The patient
was ﬁnally discharged from our hospital without severe disability. ECMO should be considered one of the
treatment options for the management of ARDS due to severe pulmonary tuberculosis.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In-hospital mortality of tuberculosis patients remains high,
especially among those requiring admission to the intensive care
unit (ICU) and mechanical ventilation (MV) [1,2]. Tuberculosis pa-
tients requiring ICU care may also develop acute respiratory
distress syndrome (ARDS) [1,3]. In the management of patients
with ARDS, extracorporeal membrane oxygenation (ECMO) has
been successfully used as salvage therapy. ARDS severe enough tondrome; ECMO, extracorpo-
MV, mechanical ventilation;
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Ltd. This is an open access article urequire ECMO support is estimated to occur in nearly 5 to 10 cases
per million population per year [4]. The effectiveness of ECMO in
ARDS patients with pneumonia, inﬂuenza A (H1N1) and trauma has
recently been described but is less certain in ARDS patients with
pulmonary tuberculosis (PTB) [5,6]. We report a patient with ARDS
due to severe PTB who was rescued by ECMO.
2. Case report
A-48-year-old man was admitted to our hospital because of
dyspnea. His sputa were strongly smear-positive and the myco-
bacteria obtained from culture were identiﬁed as Miliary tubercu-
losis. Routine blood tests showed white blood cell count of 12800/
mm3, platelets of 35.0  104/mm3, C-reactive protein of 22.0 mg/dl,
albumin level of 1.9 g/dl and a negative HIV ELISA test. His chest X-
ray and computed tomography showed diffuse bilateral inﬁltration
and cavity (Fig. 1A, B), and blood gas test showed PaO2/FiO2 131.0.
This patient was initially hospitalized in the ICU and noninvasive
positive-pressure ventilation started. Anti-tuberculosis drugs,nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest X-ray and computed tomography images. (A) and (B): On the day of admission to our hospital. (C) and (D): 3 days after the discontinuation of extracorporeal membrane
oxygenation. (E) and (F): 2 weeks after weaning from mechanical ventilation.
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antibiotics including meropenem and ciproﬂoxacin; and intrave-
nous methylprednisolone (1.0 mg/kg/day) were introduced.
Six days later, further deterioration of gas exchange prompted
the decision to intubate and steroid pulse therapy consisting of
intravenous methylprednisolone (1000 mg/day for 3 days) fol-
lowed by intravenous methylprednisolone (1.0 mg/kg/day) was
administered. However, on the 3rd day of intubation arterial blood
gas analyses showed severe hypoxemia (PaO2/FiO2 60.4) refractory
to conventional MV, and we decided to administer veno-venous
ECMO. Ventilator settings were adjusted to provide lung rest
(pressure controlled ventilation with peak pressure of 20 cmH2O,
PEEP of 10 cmH2O, and ventilation frequency of 8 per minute).
Hemoptysis was observed on day 27 after the start of ECMO but
ceased with adjustment to a lower dosage of heparin. No other
ECMO-related major complications were evident during treatment.
The pulmonary inﬁltrate and oxygenation status gradually
improved (Fig. 1C, D, E, F), and the systemic corticosteroid was
tapered. ECMO was discontinued on day 52 and we successfully
weaned the patient from MV 106 days after the start of adminis-
tration of ECMO. After a hospital stay and rehabilitation of 10
months, he was discharged from our hospital without severe
disability.Table 1
Previously reported patients with pulmonary tuberculosis treated with ECMO.
Age Sex Underlying condition Treatment Use of corticos
58 F None None None
15 F None INH/RFP/EB/PZA None
20 M None INH/RFP/EB/PZA None
14 F Histiocytic hemophagocytosis INH/RFP/EB/PZA Methylprednis
24 F Laryngeal papilloma INH/RFP/EB/PZA Methylprednis
20 M None INH/RFP/EB/PZA None
EB ¼ ethambutol; ECMO ¼ extracorporeal membrane oxygenation; INH ¼ isoniazid; PZ3. Discussion
ECMO is considered one of the treatment options for severe
ARDS [5e7]. ARDS is an infrequent but serious complication of PTB
[8]. The mortality of ARDS patients with PTB requiring MV is rela-
tively high compared with that of patients with ARDS from other
causes [9]. Five patients with acute respiratory failure due to PTB
were recently reported to be successfully rescued by ECMO [10e15]
(Table 1). Given the high mortality rate of ARDS patients with PTB,
ECMO could be an important treatment option.
An innovative aspect of this case is the duration of ECMO, which
was longer than that in ARDS from other causes. The clinical
courses of patients with PTB often become indolent and the healing
rate of PTB is characteristically slow. In addition, our patient
showed severe hypoxia compared with previous patients with
ARDS from PTB treated with MV [9]. A previous study reported that
PTB patients with greater disease extent and severity showed
persistent inﬂammation and required longer treatment [16]. While
there is some concern that long-term use of ECMO may lead to a
higher risk of complications, recent progress in the techniques and
equipment used in ECMO have made prolonged ECMO support
feasible. In fact, the survival of prolonged ECMO patients has
improved signiﬁcantly compared with previous years [17]. Anotherteroid Length of ECMO Outcome Author/year
5 days Death Homan W 1975 [10]
6 days (152 h) Recovery Petrillo TM 2001 [11]
89 days Recovery Mauri T 2012 [12]
olone 2mg/kg/day 6 days recovery Monier B 2013 [13]
olone 250mg/day 36 days Recovery Andresen M 2013 [14]
89 days Recovery Cogliandro V 2014 [15]
A ¼ pyrazinamide; RFP ¼ refampicin.
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by Nocardia cyriacigeorgica and Burkholderia cepacia that was
rescued by ECMO [18].
In this patient the adjunctive use of systemic corticosteroid
therapy led to rapid clinical improvement and allowed us to wean
the patient off ECMO earlier. Andresen et al. similarly reported that
systemic corticosteroid therapy during ECMO support led to pro-
gressive improvement of respiratory function [14]. Several other
studies have also suggested the effectiveness of adjunctive use of
corticosteroids for PTB [19e21]. The steroid dose we used in this
case was higher than that in the previous reports. Although evi-
dence for high dose steroid therapy for PTB is still lacking, our aim
in using this high dose was to get quicker and stronger results and
to decrease the need for long-term steroid use [22].
In conclusion, we have reported here a patient with ARDS due to
severe PTB who was rescued by ECMO. The healing rate of PTB is
characteristically slow, which may lead the long-term use of ECMO.
There is increasing recent evidence for the effectiveness of ECMO,
and advances in the techniques and devices have made prolonged
ECMO support feasible. ECMO should therefore be considered
among the treatment options in patients with ARDS due to severe
PTB when conventional ventilatory support is inadequate.
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